But, who will make all the empty promises..if Kellum goes? Nov. 12 2021
Dr. John Kellum, Chief Medical Officer of Spectral, commented, “We remain focused on the start of our DIMI usability trial for home use of this exciting new device aimed at a $5.3 billion U.S. home dialysis market. We had anticipated first patient enrollment into the DIMI usability trial at the beginning of Q4 2021, but now expect to begin the trial in Q1 2022
May 13 2022
Dr. John Kellum, Chief Medical Officer of Spectral, further noted, “We continue to advance the development and commercialization of our SAMI and DIMI devices through our Dialco Medical subsidiary. We remain focused on the start of our DIMI usability trial for home use and we expect first patient enrollment in the third quarter of 2022 with a study duration of approximately 18 months…”